AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02229773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS low dose
Study NCT02229773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02229773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study NCT01764347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided prostate biopsy
Description: Undergo MRI-TRUS fusion image-guided prostate biopsy
Study NCT02229773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS medium dose
Study NCT02229773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS high dose
Study NCT01764347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI-TRUS fusion image-guided prostate biopsy
Study NCT02089997 — intervention group
Intervention type: DRUG
Intervention: Sodium Risedronate
Description: Sodium risedronate tablets
Study NCT00665145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: Active drug
Study NCT00665145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03554577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.
Study NCT03554577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_A
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.
Study NCT03554577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_B
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.
Study NCT03554577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR_C
Description: Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality.
Study NCT03415802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and S-1
Description: Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)
Study NCT04036422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rejoyce (Rehabilitation Joystick for Computerized Exercise)
Description: Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
Study NCT04036422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rejoyce (Rehabilitation Joystick for Computerized Exercise)
Description: Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
Study NCT04036422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
Study NCT04036422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
Study NCT04036422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
Study NCT04036422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
Study NCT02059070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
Study NCT02059070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
Study NCT01944930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic narrow band imaging
Study NCT01944930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard white-light laparoscopy
Study NCT00394810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzem® NCD
Description: suspension, 100 mg/mL, four times daily continuous dosing
Study NCT04582318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 will be administered via IV infusion
Study NCT04582318 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NGM621
Description: NGM621 will be administered via IV infusion
Study NCT04582318 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via IV infusion
Study NCT03515967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology
Study NCT03515967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology
Study NCT02062580 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Study NCT02062580 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Study NCT04249271 — intervention group
Intervention type: OTHER
Intervention: serum sampling
Description: repeated serum sampling during pregnancy and thereafter
Study NCT00800137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low molecular weight heparin or unfractionated heparin
Description: For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. > 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery.
Study NCT00800137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin or coumadin
Description: Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be \< 3.0
Study NCT03380377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
Study NCT00176306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg IV
Description: PK in obesity
Study NCT02331095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP).
Study NCT02297932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Participants will engage in a home-based strength training program.
Study NCT02297932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants will engage in a home-based stretching training program
Study NCT02331095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Therapy
Description: Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
Study NCT02331095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation Therapy
Description: Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
Study NCT02618213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optiflow Junior
Description: Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
Study NCT02618213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Positive Airway Pressure
Description: Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
Study NCT02266953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of communication tool about diet
Description: The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
Study NCT02266953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
Study NCT04896450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Description: GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
Study NCT04896450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Description: GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
Study NCT04896450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic tooth movement (OTM)
Description: An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
Study NCT03741387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gain-frame questionnaire
Description: Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
Study NCT03741387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loss-frame questionnaire
Description: Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
Study NCT01944280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Study NCT03748615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Guided ridge splitting in posterior mandible
Description: The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation .
Study NCT03871491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
Study NCT03871491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo, administered as a single oral dose directly after randomization.
Study NCT00656890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline for injection
Description: 10mg/kg/dose sterile saline injected every other week for a total of 4 doses
Study NCT01199848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
Study NCT03640780 — intervention group
Intervention type: OTHER
Intervention: observation
Description: The surgical ages and other information between two groups were compared.
Study NCT00885820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral
Study NCT00656890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1100
Description: 10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
Study NCT03843047 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3 mg/mL nicotine strength e-liquid
Description: Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
Study NCT03843047 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6 mg/mL nicotine strength e-liquid
Description: Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
Study NCT03843047 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 12 mg/mL nicotine strength e-liquid
Description: Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
Study NCT03843047 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 24 mg/mL nicotine strength e-liquid
Description: Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
Study NCT02229201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4-6 mg/kg/h during anaesthesia
Study NCT02229201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 0.8 MAC
Study NCT03772912 — intervention group
Intervention type: DEVICE
Intervention: HEMOBLAST Bellows
Description: The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
Study NCT03314805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus polysaccharides 500 mg
Description: PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
Study NCT03314805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
Study NCT03314805 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EC Chemotherapy
Description: Epirubicin plus Cyclophosphamide every 21 days
Study NCT03314805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EC Chemotherapy
Description: Epirubicin plus Cyclophosphamide every 21 days
Study NCT01639326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan high doses
Description: Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
Study NCT01639326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan standard doses
Description: Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
Study NCT01126580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT01126580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Study NCT01126580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (oral)
Study NCT01126580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (subcutaneous)
Study NCT01199848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10G
Description: whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
Study NCT01199848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20G
Description: whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
Study NCT01199848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40G
Description: whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
Study NCT01199848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebonofiber
Description: Placebo without Fiber
Study NCT02550899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal submucosal injection group 1
Description: Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
Study NCT02550899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal submucosal injection group 2
Description: Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
Study NCT02550899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal submucosal injection group 3
Description: Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
Study NCT03560973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: ramucirumab/ placebo was added to gemcitabine